&w=3840&q=100)
10 years as CEO, $1 billion richer: Sundar Pichai rides Alphabet's AI wave
According to the Bloomberg Billionaires Index, Pichai's estimated wealth stands at $1.1 billion. Forbes' Real-Time Billionaires list puts it slightly higher at $1.2 billion.
Dip in salary, but net worth rises
Interestingly, Pichai's overall compensation dropped sharply in 2024. According to Alphabet's annual report, he earned $10.72 million this year — down from a staggering $226 million in 2022. The steep fall was due to the absence of a large stock grant he received in 2022, which is awarded once every three years.
Despite the drop, his base salary has remained steady at $2 million annually. The rest of his earnings typically come from stock-based compensation and perks.
Alphabet also increased its spending on his personal security in 2024. The company spent $8.27 million — 22 per cent more than last year — on services including residential security, monitoring, consultation, and travel protection.
Alphabet's stock rally fuels billionaire status
Pichai's growing wealth is largely tied to Alphabet's robust performance in the second quarter of 2024. The tech giant reported better-than-expected profits of $28.2 billion on revenue of $96.4 billion.
Following the earnings announcement, Alphabet's stock surged by 4.1 per cent — its largest single-day gain in two months. This bump also lifted Pichai's net worth, as he holds a 0.02 per cent stake in the company.
Alphabet is currently valued at about $440 billion. The latest financial results reflect the company's growing investment in artificial intelligence, which is boosting multiple business verticals, including Cloud, YouTube, and Google Play.
Alphabet to boost AI investments to $85 bn
Alphabet plans to significantly increase capital spending in 2025 to keep up with the booming demand for AI services. The company now estimates $85 billion in capital expenditures — $10 billion more than its previous forecast, Bloomberg reported.
Though the initial reaction in after-hours trading was mixed, investors regained confidence after Pichai clarified that the hike is essential to meet customer needs in the AI space. Sales excluding traffic acquisition costs climbed to $81.7 billion, beating Bloomberg's analyst average estimate of $79.6 billion.
From Tamil Nadu to Silicon Valley
Born in Tamil Nadu, Pichai earned a scholarship to Stanford University in 1993. He joined Google in 2004 and rose through the ranks, leading teams behind Chrome and Android before becoming the chief executive in 2015.
Despite his billionaire status, Pichai holds a relatively small stake in Alphabet and most of his wealth is in cash.
Alphabet co-founders Larry Page and Sergey Brin remain among the world's wealthiest individuals, with net worths of $171.2 billion and $160.4 billion, respectively.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 minutes ago
- Time of India
Trump calls India's economy 'dead' – but that makes no sense
Recently, Donald Trump, the former U.S. President, made fun of India's economy by calling it 'dead.' But that's a strange and silly thing to say. Think about it: An economy is alive as long as people are buying, selling, and trading things — even if it's just one person giving a teabag to a friend in exchange for some biscuits. That's still trade! India has over 1.4 billion people, which means there are tons of trades and businesses happening every second. So how can it be 'dead'? Also, if India's economy was really dead, why is Trump so eager to sell things like soybeans, corn, and butter to India? You don't trade with something that isn't working. He even spent four months trying to make a trade deal — and only gave up when he got frustrated and added extra taxes (called tariffs) on Indian goods. India's economy is actually growing faster than any other big country's right now. That's not what a dead economy looks like. Even countries that aren't growing fast — like Japan — are still very much alive and running. Trump has said strange things before. Once, he told a man his father would be proud 'looking down on him,' thinking the father had passed away. But the man said his dad was still alive. Trump just replied, 'Then he's even more proud!' So when Trump says 'dead,' it might not mean what you think — or it might not mean anything at all. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Mint
6 minutes ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
The Hindu
36 minutes ago
- The Hindu
Trump welcomes reports India may halt Russian oil imports, calls it a 'good step'
U.S. President Donald Trump on Friday (August 1, 2025) expressed cautious optimism over reports that India may be ending its purchases of Russian oil, calling it a 'good step' while addressing reporters before departing the White House. 'I understand India no longer is going to be buying oil from Russia. That's what I heard. I don't know if that's right or not, but that's a good step,' Mr. Trump said during an impromptu press gaggle on the South Lawn. His remarks come amid growing American scrutiny of India's continued energy and defence ties with Russia, especially in the context of the ongoing war in Ukraine and broader U.S. efforts to isolate the Kremlin economically. While there has been no official confirmation from New Delhi regarding such a move, Mr. Trump's comments mark the first public acknowledgement from the U.S. administration of a potential policy shift by India. Mr. Trump has maintained a firm stance against countries maintaining close commercial ties with Moscow. His administration has already imposed a 25% tariff on Indian imports, citing both trade imbalances and India's longstanding energy relationship with Russia. In his remarks, Mr. Trump did not elaborate on whether the reported change in India's oil policy would impact those tariffs or future negotiations. 'We'll see what happens,' he said. The issue of India's energy imports from Russia has been a point of contention between Washington and New Delhi, with previous administrations urging India to reduce its reliance on Russian crude in the wake of the Ukraine conflict. India has so far defended its purchases as essential for energy security and economic stability. Mr. Trump's tone on Friday, however, suggested an openness to engage with India if the reported shift holds. 'That's a good step,' he repeated, signalling potential diplomatic movement should the reports prove accurate. Officials in New Delhi have historically avoided commenting on energy policy decisions until after implementation. Mr. Trump's brief but pointed remarks come as part of a broader foreign policy strategy to pressure both adversaries and allies into realigning their global partnerships in accordance with US strategic interests. Russia remains under sweeping U.S. sanctions, and energy exports have been a critical lifeline for the Kremlin amid ongoing war-related expenditures. (This article is published in an arrangement with 5WH.)
